Quarterly ResultAug 12, 2026, 04:17 PM
SeaStar Medical Q2 Revenue $0.6M, up 82%; Net Loss $3.7M
AI Summary
SeaStar Medical reported Q2 2026 net revenue of $0.6 million, an 82% increase year-over-year, driven by increased demand for its QUELIMMUNE therapy. The company's net loss widened to $3.7 million, or $0.91 per share, compared to a net loss of $2.0 million, or $1.77 per share, in Q2 2025. Key business advancements include adding three new children's hospitals to its QUELIMMUNE customer base, advancing enrollment in the NEUTRALIZE-AKI pivotal clinical trial, and obtaining ICD-10-PCS codes for its SCD therapy.
Key Highlights
- Net revenue for Q2 2026 increased 82% to $0.6 million from $0.3 million in Q2 2025.
- Net loss for Q2 2026 was $3.7 million, or $(0.91) per share, compared to $2.0 million, or $(1.77) per share, in Q2 2025.
- Added 3 new children's hospitals for QUELIMMUNE®, bringing total customers to 20.
- Advanced NEUTRALIZE-AKI trial enrollment to 223 of 339 adult AKI patients.
- Obtained ICD-10-PCS codes for SCD therapy, effective October 1, 2026.
- Cash balance at June 30, 2026, was $7.0 million.
- Gross margins for Q2 2026 were 91%.
Price Impact
More from ICU